Venetoclax Combinations in AML: VIALE-A, VIALE-C, and Practical Challenges

This episode, "Venetoclax Combinations in AML: VIALE-A, VIALE-C, and Practical Challenges," features the panel examining the drug that has become central to nearly every AML treatment discussion.

Dr. Zeidan describes how venetoclax has reshaped AML management over his career. For many years, patients who could not receive intensive chemotherapy had few meaningful options. Venetoclax has limited activity as monotherapy, so it was developed in combination. It was first approved with azacitidine or decitabine, and with low-dose cytarabine, which is rarely used in the US. It is now the standard of care for older, unfit patients. Trials are also combining venetoclax with intensive regimens, including a large European phase 3 study adding it to 7+3 that he believes could be practice changing. On the azacitidine-venetoclax backbone, it is being combined with FLT3, IDH, and menin inhibitors. He cautions that its drug interactions and dose modifications create real outpatient challenges. Older patients take many medications and can become confused about when to start, stop, or reduce doses.

Dr. Stein reviews the data guiding treatment selection. For newly diagnosed patients appropriate for lower-intensity therapy and naive to hypomethylating agents, the standard is a hypomethylating agent plus venetoclax. That standard rests on VIALE-A, which showed median overall survival of 14.7 months versus 9.6 months with azacitidine alone. Patients with prior hypomethylating agent exposure for MDS were ineligible and enrolled instead in VIALE-C. That trial compared low-dose cytarabine with or without venetoclax. Its primary analysis showed no significant survival benefit, though six months of additional follow-up did. In practice, Dr. Stein adds venetoclax to the existing hypomethylating agent for a cycle or two, citing retrospective response rates of 40% to 50%. Low-dose cytarabine is reserved for later, with clinical trials considered at that point. Dr. Mahmoudjafari notes that low-dose cytarabine is operationally complex. Dr. Stein explains that New York patients can self-inject at home, and Dr. Mahmoudjafari adds that this falls under a different insurance benefit.

The next episode in this series, "AML Targeted Therapies, Molecular Testing, and Limitations of Current Regimens," features Dr. Murthy on molecular testing and Dr. Zeidan on the limits of today's regimens.